Nepafenac 3 MG/ML Ophthalmic Suspension [Ilevro] — RxCUI 1365866
RxNorm drug concept · Semantic branded drug
RxCUI 1365866
Semantic branded drug · SBD
● Current RxNorm concept 2 FDA products
1 package NDC
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI1365866
Official nameNepafenac 3 MG/ML Ophthalmic Suspension [Ilevro]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asIlevro 0.3 % Ophthalmic Suspension; Ilevro 3 MG/ML Ophthalmic Suspension
FDA products mapped2
Package NDCs mapped1
Reported Medicaid activity (SDUD)582 prescriptions · 6 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Nepafenac Ophthalmic: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- This drop is used to control pain and swelling in your eye after cataract surgery. It belongs to a class of medicines called NSAIDs — the same family as ibuprofen — but in eye drop...
- For Ilevro 0.3%, you start one drop in the affected eye the day before your surgery. On the day of surgery, you put in your regular daily drop and then an extra drop 30 to 120 minu...
- No — do not put your contact lenses in while you are using this medication. This is an important precaution during your recovery period.
- Can I wear my contact lenses while using this?
🕸️ Concept Web — How Nepafenac 3 MG/ML Ophthalmic Suspension [Ilevro] Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Nepafenac 3 MG/ML Ophthalmic Suspension [Ilevro]
RxCUI 1365866 Semantic branded drug · SBD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Nepafenac
298665IN
-
Nepafenac
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Ilevro
1365862BN
-
Ilevro
-
Dose forms 6
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Nepafenac Ophthalmic Suspension
578043SCDF -
Nepafenac Ophthalmic Product
1158407SCDG -
Nepafenac Ophthalmic Suspension [Ilevro]
1365864SBDF -
Ilevro Ophthalmic Product
1365865SBDG -
Ophthalmic Suspension
316964DF -
Ophthalmic Product
1151135DFG
-
Nepafenac Ophthalmic Suspension
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Nepafenac 3 MG/ML Ophthalmic Suspension
1362132SCD -
Nepafenac 3 MG/ML
1362131SCDC -
Nepafenac 3 MG/ML [Ilevro]
1365863SBDC
-
Nepafenac 3 MG/ML Ophthalmic Suspension
Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Nepafenac 3 MG/ML Ophthalmic Suspension
SCD · 1362132 -
Nepafenac 3 MG/ML
SCDC · 1362131 -
Nepafenac Ophthalmic Suspension
SCDF · 578043 -
Nepafenac Ophthalmic Product
SCDG · 1158407
Brand-Name Concepts
-
Nepafenac 3 MG/ML [Ilevro]
SBDC · 1365863 -
Nepafenac Ophthalmic Suspension [Ilevro]
SBDF · 1365864 -
Ilevro Ophthalmic Product
SBDG · 1365865 -
Ilevro
BN · 1365862
📦 FDA Products & Package NDCs
2 products · 1 package NDC
1 package NDC map to RxCUI 1365866 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 82667-0400-03 | 1 BOTTLE, PLASTIC in 1 CARTON (82667-400-03) / 3 mL in 1 BO... | ILEVRO | Harrow Eye, LLC | 2024-05-01 |
Observed labelers:
Harrow Eye, LLC (1)
· +1 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
💲 Pricing (NADAC)
NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ml · median
$121.1220
Range $121.1220–$121.1220
· middle 50% $121.1220–$121.1220
· 1 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.